# US 2015/0147764 A1 · Polypeptide substrate for the detection of von williebrand factor cleaving protease adamts13

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147764 A1
- Document ID: US20150147764A1
- Status: Published application
- Kind: A1
- Application number: 14/357,988
- Filed: 2012-11-09
- Published: 2015-05-28
- Earliest claimed: 2011-11-11
- Assignees: Immucor Gti Diagnostics, Inc.
- Inventors: Gian Paolo Visentin; Suzette Chance; Elizabeth Wuitschick
- Web page: https://patentgrep.com/patent/US20150147764A1

## CPC

- C12Q 1/37: involving peptidase or proteinase
- C07K 14/755: Factors VIII {, e.g. factor VIII C (AHF), factor VIII Ag (VWF)}
- G01N 33/573: for enzymes or isoenzymes
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- G01N 2333/755: Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]
- G01N 2333/96486: Metalloendopeptidases (3.4.24)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

In a first aspect, there is provided an isolated polypeptide substrate for a disintegrin-like and metallopeptidase with thrombospondin type-1 motif, 13 (ADAMTS13) that is from 45 to 70 amino acids in length and has an amino acid sequence that is substantially similar to part of the von Willebrand factor A2 domain sequence set forth in SEQ ID NO:2, with one or more of the following modifications: (i) the amino acid corresponding to position 1599 of SEQ ID NO: 2 is mutated from Q to K; (ii) the amino acid corresponding to position 1610 of SEQ ID NO: 2 is mutated from N to C; and (iii) the amino acids corresponding to Q1624 to R1641 of SEQ ID NO: 2 are deleted. In another aspect, there is provided an ADAMTS13 polypeptide substrate that is from 50 to 75 amino acids in length and has an amino acid sequence that is substantially similar to part of the von Willebrand factor A2 domain sequence set forth in SEQ ID NO:2, with one or more of the following modifications: (i) the amino acid corresponding to position 1599 of SEQ ID NO: 2 is mutated from Q to K; (ii) the amino acid corresponding to position 1610 of SEQ ID NO: 2 is mutated from N to C; (iii) the amino acid corresponding to position 1629 of SEQ ID NO: 2 is mutated from G to E; and (iv) the amino acids corresponding to G1631 to R1641 of SEQ ID NO: 2 are deleted.

## Claims

### Claim 1

An isolated polypeptide substrate for a disintegrin-like and metallopeptidase with thrombospondin type-1 motif, 13 (ADAMTS13) that is from 45 to 70 amino acids in length and has an amino acid sequence that is substantially similar to part of the von Willebrand factor A2 domain sequence set forth in SEQ ID NO:2, with one or more of the following modifications:
(i) the amino acid corresponding to position 1599 of SEQ ID NO: 2 is mutated from Q to K;
(ii) the amino acid corresponding to position 1610 of SEQ ID NO: 2 is mutated from N to C; and
(iii) the amino acids corresponding to Q1624 to R1641 of SEQ ID NO: 2 are deleted.

### Claim 2

An ADAMTS13 polypeptide substrate that is from 50 to 75 amino acids in length and has an amino acid sequence that is substantially similar to part of the von Willebrand factor A2 domain sequence set forth in SEQ ID NO:2, with one or more of the following modifications:
(i) the amino acid corresponding to position 1599 of SEQ ID NO: 2 is mutated from Q to K;
(ii) the amino acid corresponding to position 1610 of SEQ ID NO: 2 is mutated from N to C;
(iii) the amino acid corresponding to position 1629 of SEQ ID NO: 2 is mutated from G to E; and
(iv) the amino acids corresponding to G1631 to R1641 of SEQ ID NO: 2 are deleted.

### Claim at position 3

-5. (canceled)

### Claim 6 (depends on 2)

The ADAMTS13 polypeptide substrate according to claim 2, wherein the detectable label is a fluorophore and a quencher.

### Claim at position 5

-9. (canceled)

### Claim 10

A lyophilized polypeptide substrate, wherein the substrate is from 45 to 70 amino acids in length and has an amino acid sequence that is substantially similar to part of the von Willebrand factor A2 domain sequence set forth in SEQ ID NO:2, with one or more of the following modifications:
(i) the amino acid corresponding to position 1599 of SEQ ID NO: 2 is mutated from Q to K;
(ii) the amino acid corresponding to position 1610 of SEQ ID NO: 2 is mutated from N to C;
(iii) the amino acid corresponding to position 1629 of SEQ ID NO: 2 is mutated from G to E; and
(iv) the amino acids corresponding to Q1624 to R1641 of SEQ ID NO: 2 are deleted.

### Claim 11 (depends on 1)

A lyophilized polypeptide substrate for a disintegrin-like and metallopeptidase with thrombospondin type-1 motif, 13 (ADAMTS13) according to claim 1.

### Claim 12 (depends on 1)

A method for cleaving the ADAMTS13 polypeptide substrate according to claim 1, comprising contacting said ADAMTS13 polypeptide substrate with an ADAMTS13 protease.

### Claim 13 (depends on 1)

A method for measuring ADAMTS13 activity in a sample comprising the use of the ADAMTS13 polypeptide substrate according to claim 1.

### Claim 14 (depends on 1, 13)

The method according to claim 13, comprising the steps of:
(a) providing a sample comprising, or suspected of comprising, an ADAMTS13;
(b) contacting said sample with the ADAMTS13 polypeptide substrate according to claim 1; and
(c) determining the fragmentation of the ADAMTS13 polypeptide substrate, wherein the fragmentation of the ADAMTS13 polypeptide substrate is optionally compared to one or more controls and/or calibrators in order to arrive at a measurement of ADAMTS13 activity.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the cleavage of the ADAMTS13 polypeptide substrate is measured by monitoring the change in fluorescence.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the ADAMTS13 polypeptide substrate is in solution in step (b).

### Claim 17 (depends on 14)

The method according to claim 14, wherein the ADAMTS13 polypeptide substrate attached to a solid support.

### Claim at position 14

-20. (canceled)

### Claim 21 (depends on 1)

A kit for in vitro testing of ADAMTS13 activity in a subject, comprising the ADAMTS13 polypeptide substrate according to claim 1, one or more calibrators containing a known concentration of ADAMTS13 activity and/or one or more positive controls for ADAMTS13 activity optionally together with a specimen diluent and/or a substrate buffer.

### Claim 22

(canceled)
